Aeglea Biotherapeutics, Inc. (AGLE) 10-K Annual Report March 2022

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 Par Value Per Share

AGLE

The Nasdaq Stock Market LLC

(Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

The following information was filed by Aeglea Biotherapeutics, Inc. (AGLE) on Wednesday, February 9, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1636282/000156459022008995/agle-10k_20211231.htm

View differences made from one year to another to evaluate Aeglea Biotherapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aeglea Biotherapeutics, Inc..

Continue

Assess how Aeglea Biotherapeutics, Inc.'s management team is paid from their Annual Proxy

Aeglea Biotherapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Revenue

Financial

Other

Filter Subcategory:

All

Product

Expense

Other

Inside Aeglea Biotherapeutics, Inc.'s 10-K Annual Report:

Revenue - Product Highlight
In July 2020, we filed a shelf registration statement on Form S-3 that was declared effective by the SEC for the potential offering, issuance and sale by us of up to $400.0 million of our common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock and debt securities, subscription rights to purchase common stock and units consisting of all or some of these securities.

Financial - Shares Highlight
The shares of common stock and pre-funded warrants sold in the 2020 Public Offering were pursuant to a shelf registration statement on Form S-3, declared effective in February 2019 by the SEC for the potential offering, issuance and sale by us of up to $200.0 million of our common stock, warrants to purchase common stock, and other security types and subscription rights.
Revenue - Product Highlight
The net change in operating assets and liabilities of $1.8 million was primarily related to a $3.6 million increase in deferred revenue due to receiving a $21.5 million upfront payment under the Immedica Agreement offset by the recognition of revenue allocated to the license, PEACE Phase 3 trial and BLA filing.
Financial - Expense Highlight
These increases will likely include higher costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses.
Financial - Shares Highlight
We sold 15,442,303 shares of common stock and pre-funded warrants to purchase up to 13,610,328 shares of common stock in an underwritten public offering, or the 2020 Public Offering, for gross proceeds of $138.0 million, resulting in net proceeds of $129.0 million after deducting underwriting discounts, commissions, and offering costs.
Financial - Expense
We anticipate that our expenses...Read more
Other - Other
Under the terms of the...Read more
Financial - Expense
Additional offsets included a $1.2...Read more
Other - Other
Accordingly, based on recurring losses...Read more
Financial - Expense
The process of conducting the...Read more
Financial - Expense
General and administrative expenses increased...Read more
Financial - Expense
Research and development expenses decreased...Read more
Financial - Expense
Our research and development expenses...Read more
Other - Other
Since we are a clinical-stage...Read more
Revenue - Product
Such royalties are payable for...Read more
Other - Other
The Restated License was amended...Read more
Revenue - Product
In addition, we are required...Read more
Revenue - Product
We have recognized license and...Read more
Revenue - Product
The estimates made on an...Read more
Other - Other
Changes in these estimates that...Read more
Financial - Expense
Inputs, such as the services...Read more
Financial - Expense
We accrue for expenses resulting...Read more
Financial - Expense
The net change in operating...Read more
Financial - Expense
The capitalized amounts are expensed...Read more
Financial - Expense
The increase in general and...Read more
Other - Other
For Arginase 1 Deficiency, which...Read more
Financial - Expense
Additionally, we have incurred and...Read more
Revenue - Product
In the future, we may...Read more
Other - Other
In addition, we have based...Read more
Other - Other
These estimates are typically based...Read more
Other - Other
Based on the terms and...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Aeglea Biotherapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.20: Material Contract

Exhibit 10.21: Material Contract

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: AGLE
CIK: 1636282
Form Type: 10-K Annual Report
Accession Number: 0001564590-22-008995
Submitted to the SEC: Tue Mar 08 2022 7:09:20 AM EST
Accepted by the SEC: Tue Mar 08 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/agle/0001564590-22-008995.htm

Aeglea Biotherapeutics, Inc. (AGLE) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

AGLE Valuations

AGLE Annual Reports

AGLE Quarterly Reports

AGLE Corporate News